bims-metalz 2023-07-02 papers

Issue of 2023–07–02
four papers selected by
Mikaila Chetty, Goa University

APMIS. 2023 Jun 26.

Dynamic distribution of gut microbiota during Alzheimer's disease progression in a mice model.

Jianshen Zhu, Shuyun Liu, Haoran Zhang, Wenjing Zhao, Jinmei Ding, Ronghua Dai, Ke Xu, Chuan He, Jiajia Liu, Lingyu Yang, He Meng.

Alzheimer's disease (AD) is an irreversible neurodegenerative disease that affects more than 44 million people worldwide. The pathogenic mechanisms of AD still remain unclear. Currently, there are numerous studies investigating the microbiota-gut-brain axis in humans and rodents indicated that gut microbiota played a role in neurodegenerative diseases, including AD. However, the underlying relationship between the progress of AD disease and the dynamic distribution of gut microbiota is not well understood. In the present study, APPswe /PS1ΔE9 transgenic mice of different ages and sex were employed. After the evaluation of the AD mice model, gut metagenomic sequencing was conducted to reveal gut microbiota, moreover, probiotics intervention was treated in the AD mice. The results showed that (1) AD mice had reduced microbiota richness and a changed gut microbiota composition, and AD mice gut microbiota richness was correlated with cognitive performance. We have also found some potential AD-related microbes, for example, in AD-prone mice, the genus Mucispirillum was strongly associated with immune inflammation. (2) Probiotics intervention improved cognitive performance and changed gut microbiota richness and composition of AD mice. We revealed the dynamics distribution of gut microbiota and the effect of probiotics on AD in a mice model, which provides an important reference for the pathogenesis of AD, intestinal microbial markers associated with AD, and AD probiotic intervention.

Keywords: Alzheimer's disease; dynamic distribution; gut microbiota; mice model; probiotics

DOI: https://doi.org/10.1111/apm.13339

Front Aging Neurosci. 2023 ;15 1215586

Editorial: Nutritional interventions on age-related neurodegenerative diseases.

Tiantian Zhang, Zhigang Liu, Yashi Mi.

Keywords: diet; dietary recommendations; multi-target; neurodegenerative diseases; nutrition; sea-land combination

DOI: https://doi.org/10.3389/fnagi.2023.1215586

Microorganisms. 2023 Jun 08. pii: 1527. [Epub ahead of print]11(6):

Therapeutic Prospect of New Probiotics in Neurodegenerative Diseases.

Mingxia Bi, Chang Liu, Yulin Wang, Shuang-Jiang Liu.

Increasing clinical and preclinical evidence implicates gut microbiome (GM) dysbiosis as a key susceptibility factor for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD). In recent years, neurodegenerative diseases have been viewed as being driven not solely by defects in the brain, and the role of GM in modulating central nervous system function via the gut-brain axis has attracted considerable interest. Encouraged by current GM research, the development of new probiotics may lead to tangible impacts on the treatment of neurodegenerative disorders. This review summarizes current understandings of GM composition and characteristics associated with neurodegenerative diseases and research demonstrations of key molecules from the GM that affect neurodegeneration. Furthermore, applications of new probiotics, such as Clostridium butyricum, Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bacteroides fragilis, for the remediation of neurodegenerative diseases are discussed.

Keywords: Akkermansia muciniphila; Bacteroides fragilis; Clostridium butyricum; Faecalibacterium prausnitzii; gut microbiome; neurodegenerative diseases; probiotics

DOI: https://doi.org/10.3390/microorganisms11061527

Trends Endocrinol Metab. 2023 Jun 23. pii: S1043-2760(23)00092-9. [Epub ahead of print]

Apolipoprotein E in lipid metabolism and neurodegenerative disease.

Linda G Yang, Zachary M March, Roxan A Stephenson, Priyanka S Narayan.

Dysregulation of lipid metabolism has emerged as a central component of many neurodegenerative diseases. Variants of the lipid transport protein, apolipoprotein E (APOE), modulate risk and resilience in several neurodegenerative diseases including late-onset Alzheimer's disease (LOAD). Allelic variants of the gene, APOE, alter the lipid metabolism of cells and tissues and have been broadly associated with several other cellular and systemic phenotypes. Targeting APOE-associated metabolic pathways may offer opportunities to alter disease-related phenotypes and consequently, attenuate disease risk and impart resilience to multiple neurodegenerative diseases. We review the molecular, cellular, and tissue-level alterations to lipid metabolism that arise from different APOE isoforms. These changes in lipid metabolism could help to elucidate disease mechanisms and tune neurodegenerative disease risk and resilience.

Keywords: Alzheimer's disease; apolipoprotein E; lipid metabolism; neurodegenerative disease

DOI: https://doi.org/10.1016/j.tem.2023.05.002